Extrait

To estimate in pediatric patients, aged 2 to 17 years, with persistent fever and neutropenia, the proportion of patients treated with caspofungin reporting one or more clinical and/or laboratory drug-related adverse experience(s) during the study drug therapy period plus 14 days posttherapy.

Critère d'inclusion

• Empirical Therapy in Pediatric Patients

Liens

• euctr